DAURISMO is the first Hedgehog Pathway Inhibitor approved for the treatment of adult patients with newly diagnosed Acute Myeloid Leukemia (AML) for whom intensive chemotherapy is not an option
June 12, 2020 – Pfizer Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for DAURISMO (glasdegib), in combination with low-dose cytarabine, for the treatment of newly diagnosed and previously untreated acute myeloid leukemia (AML) in adult patients who are aged 75 years or older or who are not eligible to receive intensive induction chemotherapy.
“AML is a rapidly progressing, life-threatening blood and bone marrow cancer, and the AML community recognizes the need for innovative treatments,” says Dr. Brian Leber, Professor, Division of Hematology and Thromboembolism, Department of Medicine, McMaster University. "Today’s announcement is exciting as it gives patients across Canada living with this devastating disease and for whom intensive chemotherapy is not an option a much-needed new treatment."
“As our second medicine approved in the last 6 months for patients with acute myeloid leukemia, DAURISMO reinforces our commitment to delivering new medicines to patients living with some of the most difficult-to-treat cancers, especially those for which there are limited treatment options available,” said John Leasure, Oncology Canada Lead, at Pfizer. “We are proud to now offer these patients a new option.”
About Pfizer Canada
Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best known and most prescribed medicines and vaccines. In 2017, Pfizer Inc. invested US$ 7.65 billion globally toward developing safe and effective medicines and took part in more than 180 new R-D collaborations. Canadian headquarters of Pfizer’s Biopharmaceutical Group are located in Kirkland, Quebec. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on LinkedIn, Facebook, Twitter or YouTube.
For more information:
Corporate Affairs Canada
Pfizer Canada Media Line: 1-866-9Pfizer (1 866 973-4937)
HEALTH CANADA APPROVAL OF DAURISMO® (GLASDEGIB)